Treosulfan Exposure Predicts Thalassemia‐Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation
Clinical Pharmacology & Therapeutics · 2024-01 · 115 (1) · 116-125
DOI: 10.1002/cpt.3078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 07.11.2023. Verfasst von Aswin Anand Pai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: beta-Thalassemia, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DBT-Wellcome Trust India Alliance, Medical Research Council, Wellcome Trust.
Abstract (Originalsprache)
A toxicity‐reduced conditioning regimen with treosulfan, fludarabine, and thiotepa in patients with high‐risk β‐thalassemia major has significantly improved hematopoietic stem cell transplantation (HCT) outcomes. However, complications resulting from regimen‐related toxicities (RRTs), mixed chimerism, and graft rejection remain a challenge. We evaluated the dose–exposure‐response relationship of treosulfan and its active metabolite S, S‐EBDM, in a uniform cohort of patients with β‐thalassemia major to identify whether therapeutic drug monitoring (TDM) and dose adjustment of treosulfan is feasible. Plasma treosulfan/S, S‐EBDM levels were measured in 77 patients using a validated liquid chromatography with tandem mass spectrometry method, and the pharmacokinetic parameters were estimated using nlmixr2. The influence of treosulfan and S, S‐EBDM exposure, and GSTA1/NQO1 polymorphisms on graft rejection, RRTs, chimerism status, and 1‐year overall survival (OS), and thalassemia‐free survival (TFS) were assessed. We observed that treosulfan exposure was lower in patients with graft rejection than those without (1,655 vs. 2,037 mg•h/L, P = 0.07). Pharmacodynamic modeling analysis to identify therapeutic cutoff revealed that treosulfan exposure ≥1,660 mg•hour/L was significantly associated with better 1‐year TFS (97% vs. 81%, P = 0.02) and a trend to better 1‐year OS (90% vs. 69%, P = 0.07). Further, multivariate analysis adjusting for known pre‐HCT risk factors also revealed treosulfan exposure
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Christian Medical College, Vellore, India.
- Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India.
- Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK.
- Department of Pharmacy, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
ORCID-Profile: Aswin Anand Pai, Ezhilpavai Mohanan, John C Panetta, Uday P Kulkarni, Balaji Balakrishnan, Eunice S Edison, Anup J Devasia, Nambiathayil Aboobacker Fouzia, Anu Korula, Aby Abraham, Biju George, Alok Srivastava, Vikram Mathews, Joseph F Standing, Poonkuzhali Balasubramanian
Förderung
- DBT-Wellcome Trust India Alliance
- Medical Research Council
- Wellcome Trust
Zitieren
APA
Pai, A. A., Mohanan, E., Panetta, J. C., Kulkarni, U. P., Illangeswaran, R. S. S., Balakrishnan, B., Jayaraman, A., Edison, E. S., Lakshmi, K. M., Devasia, A. J., Fouzia, N. A., Korula, A., Abraham, A., George, B., Srivastava, A., Mathews, V., Standing, J. F., & Balasubramanian, P. (2024). Treosulfan Exposure Predicts Thalassemia‐Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical Pharmacology & Therapeutics, 115(1), 116-125. https://doi.org/10.1002/cpt.3078
Vancouver
Pai AA, Mohanan E, Panetta JC, Kulkarni UP, Illangeswaran RSS, Balakrishnan B, et al. Treosulfan Exposure Predicts Thalassemia‐Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical Pharmacology & Therapeutics. 2024;115(1):116-125. doi:10.1002/cpt.3078
BibTeX
@article{Pai2024,
author = {Pai, Aswin Anand and Mohanan, Ezhilpavai and Panetta, John C and Kulkarni, Uday P and Illangeswaran, Raveen Stephen Stallon and Balakrishnan, Balaji and Jayaraman, Agila and Edison, Eunice S and Lakshmi, Kavitha M and Devasia, Anup J and Fouzia, Nambiathayil Aboobacker and Korula, Anu and Abraham, Aby and George, Biju and Srivastava, Alok and Mathews, Vikram and Standing, Joseph F and Balasubramanian, Poonkuzhali},
title = {Treosulfan Exposure Predicts Thalassemia‐Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {115},
number = {1},
pages = {116--125},
doi = {10.1002/cpt.3078}
}
EUVIMED